急性心肌梗死并发心源性休克的遗传易感性:一项系统综述。
完整摘要 · 中文译文
背景:心源性休克(CS)使5-10%的急性心肌梗死(AMI)复杂化,并且仍与约40-50%的院内死亡率相关。已建立的临床预测因素不能完全解释为什么梗死严重程度相当的患者具有不同的结局,这提出了宿主遗传因素调节CS易感性的假说。因此,我们进行了本系统综述,以综合描述与AMI并发CS发生相关的遗传变异的已发表证据。 方法:按照PRISMA 2020指南,检索PubMed、Embase、Scopus和Cochrane Library从建库至2026年6月。符合条件的研究包括任何类型的研究,纳入成年AMI患者并报告任何特定遗传变异与CS的关联。 结果:在识别的480条记录中,9项研究符合纳入标准。报告的变异聚集为五条生物学通路:炎症/细胞因子信号传导(TNF-α -308G>A、IFN-γ +874T>A、RANTES/CCL5 -403G>A)、脂质代谢(APOE ε2/ε3/ε4)、血栓形成与纤溶(PAI-1/SERPINE1 4G/4G、MTHFR C677T/A1298C)、克隆性骨髓增殖性疾病(JAK2 V617F)以及高凝/抗氧化通路(蛋白C/S相关易栓症、PON1 Q192R)。APOE ε3/4基因型和TNF-2等位基因分别显示与CS发生率和生存率最直接的关联;JAK2 V617F和联合PAI-1/MTHFR变异见于严重、血栓驱动的CS病例表现。RANTES和PON1基因型与CS发生无关,尽管循环RANTES 水平与CS严重程度相关。 结论:现有证据有限,但迄今报道的变异涉及炎症、脂质、血栓形成和骨髓增殖等通路,提示AMI并发CS的遗传易感性具有多基因性且机制异质,需要开展前瞻性遗传关联研究。
完整摘要 · 英文原文
BACKGROUND: Cardiogenic shock (CS) complicates 5-10% of acute myocardial infarctions (AMI) and remains associated with in-hospital mortality of approximately 40-50%. The clinical predictors established do not fully explain why patients with comparable infarct severity have divergent outcomes, raising the hypothesis that host genetic factors modulate susceptibility to CS. Therefore, we conducted this systematic review to synthesize published evidence describing genetic variants associated with the development of CS complicating AMI. METHODS: PubMed, Embase, Scopus, and the Cochrane Library were searched from inception through Jun 2026, following PRISMA 2020 guidance. Eligible studies included any study type enrolling adults with AMI and reporting association of any specific genetic variants with CS. RESULTS: Of 480 records identified, 9 studies met inclusion criteria. Reported variants clustered into five biological pathways: inflammatory/cytokine signaling (TNF-α -308G>A, IFN-γ +874T>A, RANTES/CCL5 -403G>A), lipid metabolism (APOE ε2/ε3/ε4), thrombosis and fibrinolysis (PAI-1/SERPINE1 4G/4 G, MTHFR C677T/A1298C), clonal myeloproliferative disease (JAK2 V617F), and hypercoagulable/antioxidant pathways (protein C/S-related thrombophilia, PON1 Q192R). The APOE ε3/4 genotype and the TNF-2 allele showed the most direct associations with CS incidence and survival, respectively; JAK2 V617F and combined PAI-1/MTHFR variants were reported in severe, thrombus-driven case presentations of CS. RANTES and PON1 genotypes were not associated with CS occurrence, although circulating RANTES levels correlated with CS severity. CONCLUSIONS: The available evidence is limited, but the variants reported to date span inflammatory, lipid, thrombotic, and myeloproliferative pathways, suggesting that genetic susceptibility to CS complicating AMI is polygenic and mechanistically heterogeneous, requiring prospective genetic association studies.